Muscle depletion and the prediction of chemotherapy toxicity

Internal and Emergency Medicine

Volumn 8, Issue 5, 2013, Pages 373-375

  Muscaritoli, Maurizio ^a   Molfino, Alessio ^a   Rossi Fanelli, Filippo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; EDITORIAL; GENETICS; HUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SARCOPENIA;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PREDICTIVE VALUE OF TESTS; SARCOPENIA;

EID: 84880513524     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0966-2     Document Type: Editorial

References (25)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 6: 212-236.
2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27: 2758-2765.
3. Monfardini S, Falci C, Brunello A, Lonardi S, Basso U (2011) Cancer in the elderly. Intern Emerg Med 6(Suppl 1): 115-118.
4. Piccirillo JF, Tierney RM, Costas I et al (2004) Prognostic importance of comorbidity in a hospital based cancer registry. JAMA 291: 2441-2447.
5. Albini A, Donatelli F, Focaccetti C, D'Elios MM, Noonan DM (2012) Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology. Intern Emerg Med 7: 399-401.
6. Russo G, Cioffi G, Di Lenarda A et al (2012) Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 7: 439-446.
7. Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 7: 113-131.
8. Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB (2007) Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years. Pak J Med Sci Q 23: 832-839.
9. Muss HB, Berry DA, Cirrincione C, Cancer and Leukemia Group B Experience et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 25: 3699-3704.
10. American Cancer Society (2006) Cancer Facts and Figures 2006. http://www. cancer. org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006.
11. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL (2001) Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6: 441-445.
12. Bennett CL, Calhoun EA (2007) Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 12: 478-483.
13. Meyer UA (1996) Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 24: 449-459.
14. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206.
15. Saif MW (2013) Dihydropyrimidine Dehydrogenase Gene (DPYD) Polymorphism among Caucasian and non-Caucasian Patients with 5-FU- and Capecitabine-related Toxicity Using Full Sequencing of DPYD. Cancer Genomics Proteomics 10: 89-92.
16. Magnani E, Farnetti E, Nicoli D, et al (2013) Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med (Epub ahead of print). PubMed PMID: 23585145.
17. Schilsky RL (2009) Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol 27: 3725-3730.
18. Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29: 3457-3465.
19. Muscaritoli M, Molfino A, Gioia G, Laviano A, Rossi Fanelli F (2011) The "parallel pathway": a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med 6: 105-112.
20. Muscaritoli M, Lucia S, Molfino A, Cederholm T, Rossi Fanelli F (2012) Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia? Intern Emerg Med (Epub ahead of print). PubMed PMID: 22773188.
21. Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15: 2920-2926.
22. Prado CM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13: 3264-3268.
23. Nishimura M, Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21: 357-374.
24. Reuben DB, Rubenstein LV, Hirsch SH et al (1992) Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 93: 663-669.
25. Fielding RA, Vellas B, Evans WJ et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12: 249-256.